Prelude Capital Management’s AnaptysBio ANAB Stock Holding History

Prelude Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-32,023	Closed	-$595K	–	998
2025 Q1	$595K	Buy	+32,023	New	+$534K	0.05%	451
2020 Q2	–	Sell	-125	Closed	-$2K	–	1933
2020 Q1	$2K	Sell	125 -2,975	-96%	-$45.1K	﹤0.01%	1301
2019 Q4	$50K	Buy	+3,100	New	+$73.3K	﹤0.01%	1335
2019 Q2	–	Sell	-1,080	Closed	-$79K	–	1643
2019 Q1	$79K	Buy	+1,080	New	+$74.6K	﹤0.01%	998
2018 Q4	–	Sell	-14,854	Closed	-$1.48M	–	1756
2018 Q3	$1.48M	Sell	14,854 -6,540	-31%	-$543K	0.09%	261
2018 Q2	$1.52M	Buy	+21,394	New	+$1.79M	0.1%	224

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Prelude Capital Management's ANAB Position: Q2 2025 in Review

Prelude Capital Management sold out of AnaptysBio (ANAB) in Q2 2025, closing a stake of 32,023 shares — an estimated $595K sold.

Prelude Capital Management first reported a position in ANAB in Q2 2018 and held it in 6 quarters. The position peaked at $1.52M in Q2 2018. 147 funds tracked by Wall St. Rank hold ANAB as of Q2 2025.

Prelude Capital Management reported no remaining AnaptysBio position as of Q2 2025 after selling out during the quarter.
Prelude Capital Management sold 32,023 AnaptysBio shares in Q2 2025, an estimated $595K.
Prelude Capital Management first reported a position in AnaptysBio in Q2 2018 and held it in 6 quarters.
Prelude Capital Management's AnaptysBio position peaked at $1.52M in Q2 2018.
147 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.